Stay updated on Daratumumab Plus Ibrutinib in Waldenstrӧm's Clinical Trial
Sign up to get notified when there's something new on the Daratumumab Plus Ibrutinib in Waldenstrӧm's Clinical Trial page.

Latest updates to the Daratumumab Plus Ibrutinib in Waldenstrӧm's Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check20 days agoChange DetectedPage revision updated from v3.4.0 to v3.4.1, a minor update that does not modify study details or how users interact with the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check27 days agoChange DetectedAdded a glossary toggle and updated footer/version labels (Last Update Submitted that Met QC Criteria, No FEAR Act Data, Revision: v3.4.0) while removing older labels (Last Update Submitted that met QC Criteria, No FEAR Act data, Revision: v3.3.4). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check42 days agoChange DetectedRevision: v3.3.4 was added and Revision: v3.3.3 was removed.SummaryDifference0.1%

- Check63 days agoChange DetectedAdded New York as a study location under Locations and updated the page to revision v3.3.3. The previous 'New York Locations' entry and the HHS Vulnerability Disclosure link were removed.SummaryDifference0.2%

- Check91 days agoChange DetectedThe revision label updated from v3.2.0 to v3.3.2. No study-related content appears to be altered.SummaryDifference0.1%

Stay in the know with updates to Daratumumab Plus Ibrutinib in Waldenstrӧm's Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Daratumumab Plus Ibrutinib in Waldenstrӧm's Clinical Trial page.